# Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

> **NCT01641042** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 86 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine GSK134612

## Key facts

- **NCT ID:** NCT01641042
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-10
- **Primary completion:** 2014-10-10
- **Final completion:** 2015-03-03
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2017-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641042, "Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01641042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*